All In Biotech

Drug Trial Radar · NCT03031262

Efficacy and Safety of Chidamide in CBF Leukemia

Last checked: Nov 20, 2026Latest source record: May 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Feb 8, 2017

Primary completion

Apr 10, 2025

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 25, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 14 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this open-label, randomized, prospective clinical trial, CBF acute myeloid leukemia (AML) patients who have reached CR are randomised into two groups and receive high-dose cytarabine (HDAC) or high-dose cytarabine plus chidamide.The safety and efficacy of chidamide is evaluated.

Conditions

  • AML

Interventions

  • CytarabineDrug

    Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.

  • ChidamideDrug

    Chidamide at a dose of 20mg/d twice a week for 3 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relapse-Free Survival Rate (RFS)Time frame: Within 5 years after randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology & Blood Diseases Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.